The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - MorphoSys
Stock and Other Ownership Interests - MorphoSys; Roche
Patents, Royalties, Other Intellectual Property - MorphoSys; Roche
 
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Celltrion; EUSA Pharma; Gilead Sciences; Immune Design; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Portola Pharmaceuticals; Roche; Sandoz; Sanofi; SERVIER; Verastem
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Celltrion; EUSA Pharma; Gilead Sciences; Immune Design; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Portola Pharmaceuticals; Roche; Sandoz; SERVIER; Verastem
RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene (Inst); Genentech (Inst); MorphoSys (Inst)
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Thomas David Rodgers
Consulting or Advisory Role - Targeted Oncology
 
Dario Marino
No Relationships to Disclose
 
Maurizio Frezzato
Travel, Accommodations, Expenses - Celgene
 
Anna Maria Barbui
Honoraria - Janssen
Consulting or Advisory Role - Janssen
Travel, Accommodations, Expenses - Roche
 
Claudia Castellino
Research Funding - MorphoSys (Inst)
 
Erika Meli
No Relationships to Disclose
 
Nathan Hale Fowler
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; MorphoSys; Roche
Research Funding - Bristol-Myers Squibb; Celgene; Roche
 
Bruce A. Feinberg
Employment - Cardinal Health
Leadership - Cardinal Health
Stock and Other Ownership Interests - Cardinal Health
 
Sascha Tillmanns
Employment - MorphoSys
 
Stephan Parche
Employment - MorphoSys
Stock and Other Ownership Interests - MorphoSys
 
Guenter Fingerle-Rowson
No Relationships to Disclose
 
Mark Winderlich
Employment - MorphoSys
Stock and Other Ownership Interests - MorphoSys
Patents, Royalties, Other Intellectual Property - MorphoSys
 
Sumeet Vijay Ambarkhane
Employment - MorphoSys
Travel, Accommodations, Expenses - MorphoSys
 
Gilles A. Salles
Honoraria - Abbvie; Amgen; Autolus; Celgene; Gilead Sciences; Janssen; Merck; MorphoSys; Novartis; Roche/Genentech; SERVIER; Takeda
Consulting or Advisory Role - Acerta Pharma; Celgene; Epizyme; Gilead Sciences; Janssen; Kite, a Gilead company; Merck; morphosys; Novartis; Pfizer; Roche/Genentech; SERVIER
 
Pier Luigi Zinzani
No Relationships to Disclose